Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Psychoneuroimmunology: Diabetes and Cancer

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Periodontitis and incident cognitive decline and dementia: A 15-year prospective cohort study of older men residing in Northern Ireland.

Journal of Alzheimer's disease : JAD·2025

Same author

Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease.

Molecular neurodegeneration·2025

Same author

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Nature medicine·2025

Same author

Low Hand Grip Strength Is Associated with Increased Risk of Cognitive Impairment in Older Men, Including Men with Probable Sarcopenic Obesity: Results from the Northern Ireland PRIME-COG Cohort.

Gerontology·2025

Same author

Tooth loss, diet quality, and cognitive decline: A 15-year longitudinal study.

The journal of nutrition, health & aging·2025

Same author

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.

BMJ open·2024

Search research articles

Related Experiment Video

Updated: May 30, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Systemic inflammation and Alzheimer's disease.

Clive Holmes¹, Joe Butchart

¹Clinical Neurosciences Division, Moorgreen Hospital, University of Southampton, Botley Road, Southampton SO30 3JB, UK. ch4@soton.ac.uk

Biochemical Society Transactions

|July 27, 2011

Summary

Systemic inflammation exacerbates Alzheimer's disease (AD) by affecting the brain's immune system. Targeting peripheral immunity may offer new therapeutic strategies for AD.

Area of Science:

Neuroimmunology
Neuroinflammation
Alzheimer's Disease Research

Background:

Growing evidence indicates disruptions in the central innate immune system in Alzheimer's disease (AD).
Research suggests a significant interplay between the body's systemic and central innate immune responses.
Both animal models and human studies highlight this crucial communication pathway.

Purpose of the Study:

To explore the connection between systemic inflammation and central innate immune responses in neurodegenerative conditions like AD.
To investigate how systemic inflammation influences cognitive decline and sickness behavior in AD.
To identify novel therapeutic targets by understanding the manipulation of systemic innate immunity.

Main Methods:

Review of existing animal models demonstrating neurodegeneration and immune responses.

Related Experiment Videos

Last Updated: May 30, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Analysis of clinical studies examining Alzheimer's disease patients and systemic inflammation.

Comparative studies on central and systemic innate immune system interactions.

Main Results:

Animal models show heightened central immune reactions to peripheral inflammation in neurodegeneration.
Clinical studies link systemic inflammation to accelerated cognitive decline and increased sickness behavior in AD patients.
The communication between systemic and central innate immunity provides new perspectives on AD risk factors.

Conclusions:

The bidirectional communication between systemic and central innate immunity is critical in Alzheimer's disease.
Systemic inflammation emerges as a significant factor influencing AD progression.
Modulating the systemic innate immune system presents a promising avenue for novel AD therapeutics.